Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 6, 2026

$10,000 in FNGU Became $8,392 in One Session as Tech Leverage Cut Both Ways

View original at finance.yahoo.com
$10,000 in FNGU Became $8,392 in One Session as Tech Leverage Cut Both Ways Quick Read FNGU shed 16% in a single session on June 5, turning a $10,000 position into roughly $8,400, yet still holds a 28% one-year return…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • NVIDIA's 6% decline on June 5 equated to approximately $279 billion in single-session market capitalization loss.

    60% confidence

  • Despite the June selloff, FNGU remains up 28.1% over twelve months and up 6.85% year to date.

    60% confidence

  • Broadcom Q2 FY26 total revenue was $22.19 billion.

    60% confidence

  • Broadcom guided Q3 FY26 AI semiconductor revenue to $16.0 billion, representing more than 200% year-over-year growth.

    60% confidence

  • Broadcom AI semiconductor revenue compounded from $5.20 billion to $8.40 billion to $10.80 billion across the three quarters preceding Q3 FY26 guidance.

    60% confidence

  • Broadcom guided Q3 FY26 total revenue to approximately $29.4 billion.

    60% confidence

  • Broadcom Q2 FY26 non-GAAP EPS was $2.44, beating the Wall Street consensus of $2.3972.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
$10,000 in FNGU Became $8,392 in One Session as Tech Leverage Cut Both Ways — Source | Via News | Finance Via News